Searched for
HARDIK DEDHIA
Pharmeasy founder Siddharth Shah steps down as CEOPharmeasy founder Siddharth Shah has stepped down as the chief executive to assume the role of vice chairman of the company's board. Rahul ...- Taxi apps renew GST plea; PharmEasy founders start up againHappy Monday! Ride-hailing firms plan fresh appeals to the indirect tax department over GST on subscription-based services. This and more i...
- PharmEasy founders make interior design and architecture foray with All HomeThree of PharmEasy's founders — Dharmil Sheth, Dhaval Shah, and Hardik Dedhia — have launched All Home, an architectural and interior desig...
- PharmEasy to formally discuss IPO plans with its board in second trySources told ET that online pharmacy startup PharmEasy could hit the bourses this year, two years after its previous attempt. The company w...
- Return of mobile wallets; Blinkit weighs on Zomato profitHappy Tuesday! The NPCI is proposing to cut interchange fee on wallet-based UPI transactions. This and more in today’s ETtech Morning Dispa...
- PharmEasy halves loss to Rs 2,533 crore in FY24, revenue dips 15%Mumbai-based PharmEasy, operated by API Holdings Limited, reported a net loss of Rs 2,533 crore, an improvement from the Rs 5,212 crore los...
- PharmEasy CEO has three-year lock-in, Ranjan Pai to get three board seatsPai is also joining the board of PharmEasy and is expected to work with CEO Shah. He will retain the board seats as long as his holding doe...
- Goldman may convert part-debt into equity in PharmEasyThe online pharmacy is also in talks to restructure debt terms ahead of rights issue; share sale set to open on September 4
- PharmEasy valuation crash may not hit Thyrocare founder Velumani’s stakePharmEasy is faced with a steep cut in its valuation, with the new funding round pegging its shares at Rs 5 each compared to the Rs 50 per ...
- PharmEasy parent seeks shareholder nod to increase authorised share capitalThe board notified its shareholders about increasing the authorised share capital to Rs 3,500 crore (about $423.72 million), divided into 3...
- Exclusive: PharmEasy plans Rs 2,400-crore rights issue at 90% discount to repay loanMumbai-based epharmacy platform PharmEasy is likely to be valued at $500-600 million compared to the $5.6 billion valuation in 2021
- PharmEasy delays IPO, targets Ebitda breakeven by next yearThe Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...
- PharmEasy closes pre-IPO funding round at $5.6 billion valuationPharmEasy founders — Siddharth Shah, Dhaval Shah, Dhramil Sheth, Harsh Parekh and Hardik Dedhia — have received new stock options ahead of ...
- ET Startup Awards 2021: Zomato wins Startup of the Year awardZomato's blockbuster IPO—among the biggest for the Indian stock markets—not only received major institutional capital but also stirred mass...
- ET Startup Awards 2021: Nominees for Startup of the YearThe ET Startup of the Year will be characterised by breakthrough innovation, top-class execution and fast-paced growth. The quality of the ...
- Pre-IPO bout to value PharmEasy at $6 billionTalks on with Amansa, Blackstone, OrbiMed and others as e-pharmacy eyes IPO at $7-8 billion valuation.
- ETtech Exclusive: PharmEasy gets $300 million booster shot for Thyrocare dealPharmEasy has raised $300 million more, bringing the total funding received by the online pharmacy since April to $650 million, most of whi...
- PharmEasy to acquire 66% stake in Thyrocare Tech, to make open offer to grab additional 26%PharmEasy claims to be India’s number one online pharmacy and diagnostics brand. Thyrocare prides itself as the largest diagnostic company.
- PharmEasy and Ascent Health in merger talksBoards of two firms believed to have given in-principle nod for an all-stock transaction.
- Ascent Health racks up multiple acquisitions post Rs 400 crore Everstone fundingAscent Health is eyeing up to 10 acquisitions by the end of the current fiscal, according to the company’s CEO Siddharth Shah.
Load More
